CA-SCIENTIST.COM
27.10.2021 13:57:05 CEST | Business Wire | Press release
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that it’s been shortlisted in the Outstanding Innovation & Collaboration category for the British Legal Awards. Designed to enable medical researchers to spend more time on science and less on paperwork, the company’s legal framework is now used by most major pharmaceutical companies and contract research organizations (CROs).
“We have created a pharmaceutical industry legal standard that helps thousands of medical researchers do faster science,” stated Kevin Lustig, PhD, CEO and Founder of Scientist.com. “By eliminating legal, finance and operational bottlenecks, the Scientist.com marketplace empowers medical researchers in their search for new life-changing cures.”
Scientist.com has completed over $900M in sales over the past 7 years under its unique legal framework, which involves a pre-established direct contractual relationship between buyer and seller. The legal framework proved particularly useful during the COVID-19 pandemic, when there was an urgent need for scientific researchers to collaborate across the globe quickly and efficiently.
Winners of the British Legal Awards will be announced at an in-person event on November 17, 2021. For a full list of nominees visit https://www.event.law.com/legalweek-british-legal-awards/2021-shortlist
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005280/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 08:01:00 CEST | Press release
- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the durable benefits established in patients 12 years and older -- Data simultaneously published in the New England Journal of Medicine -- Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent p
PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 08:00:00 CEST | Press release
Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N
AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction11.6.2026 08:00:00 CEST | Press release
AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/ Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire) Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade. The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003. The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion. To
Curatis Increases Revenue Growth Guidance for 202611.6.2026 07:00:00 CEST | Press release
Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha
Dole Expands Year Two of Highly Successful Global Campaign With Minecraft Designed Towards Maximum Performance With New Pineapple-Focused Experience11.6.2026 07:00:00 CEST | Press release
Nutrition, hydration and energizing recipes among tips for peak gameplay Following the global success of its first healthy gaming collaboration, Dole Food Company today announced the launch of the next phase of its partnership with Minecraft, expanding the campaign with new content, experiences and a fresh focus on pineapple in connection with Dole’s 125-year pineapple heritage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609035908/en/ Dole Food Company has launched a second phase of its popular healthy gaming collaboration with Minecraft with new content, experiences and a focus on pineapples. Launching June 21 and running through October 3, 2026, the campaign builds on Dole’s mission to Make the World a Healthier Place by helping families, gaming enthusiasts and younger audiences around the globe understand how nutritious foods can fuel energy, focus and performance—both on screen and in everyday life. The new campai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom